Analysts See Upside In Novo Nordisk A/S (NVO) Driven By Diabetes And Obesity Trends

2 weeks ago 4

Rameen Kasana

Wed, December 10, 2025 astatine 9:33 AM CST 2 min read

Novo Nordisk A/S (NYSE:NVO) is among the cheap healthcare stocks to bargain heading into 2026. On December 5, Kerry Holford, an expert astatine Berenberg Bank, reaffirmed the ‘Buy’ standing connected Novo Nordisk A/S (NYSE:NVO) and kept the terms people astatine $62, suggesting an upside imaginable of astir 29%.

Earlier connected December 3, Reuters sources revealed that Novo Nordisk A/S (NYSE:NVO) volition marque its blockbuster diabetes cause Ozempic disposable successful the Indian marketplace this month. This motorboat is successful enactment with the company’s committedness to fortify its presumption successful the “world’s astir populous nation,” they added. With the second-highest fig of radical with benignant 2 diabetes and rising obesity rates, India is simply a fast-growing weight-loss solution space, which is anticipated to deed astir $150 cardinal per twelvemonth by the extremity of the decade.

Overall, Novo Nordisk A/S (NYSE:NVO) is assigned ‘Buy’ oregon equivalent ratings from astir 60% of the analysts, with a median terms people of $62.01. This implies an upside imaginable of 29.57% from the existent terms of $47.86.

Novo Nordisk A/S (NYSE:NVO) is simply a Denmark-based institution that specializes successful pharmaceutical products. Founded successful 1923, the elephantine operates done 2 segments: Diabetes and Obesity Care, and Rare Disease.

While we admit the imaginable of NVO arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.